Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31293350 | 0.92 | FAAH (0.42) | FAAHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3733255 | 0.82 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL14932456 | 0.82 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL12341085 | 0.82 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL27901314 | 0.81 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL16419554 | 0.81 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL15578408 | 0.80 | DDB1 (0.41) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL28101090 | 0.80 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL31293181 | 0.80 | DDB1 (0.39) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL1330416 | 0.80 | DDB1 (0.39) | PDE4APDE4BPDE4CPDE4DDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| WO-2012021712-A1 | TETRACYCLINE ANALOGS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021712-A1 | TETRACYCLINE ANALOGS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101415676-A | N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | FAAH 2851/4885PDE4A 4686/4885PDE4B 4683/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | FAAH 2851/4885PDE4A 4686/4885PDE4B 4683/4885 |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | FAAH 176/4885PDE4A 961/4885PDE4B 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.